jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Jan. 07, 2026

Jan. 07, 2026

jRCT2031250618

ROH-201 ophthalmic solution phase II clinical trial in patients with vernal keratoconjunctivitis

ROH-201 ophthalmic solution phase II clinical trial in patients with vernal keratoconjunctivitis

Mantani Tomomi

ROHTO Pharmaceutical Co., Ltd.

6-5-4, Kunimidai, Kizugawa, Kyoto 619-0216, Japan

+81-774-71-8802

rohtocl@rohto.co.jp

Mantani Tomomi

ROHTO Pharmaceutical Co., Ltd.

6-5-4, Kunimidai, Kizugawa, Kyoto 619-0216, Japan

+81-774-71-8802

rohtocl@rohto.co.jp

Pending

Jan. 07, 2026

12

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

Patients for whom written informed consent was obtained from the subject or a legally authorized representative
Patients with vernal keratoconjunctivitis
6 years and older at the time of informed consent

Patients who require contact lens wear
Patients who the principal/sub investigator has determined are not suitable to participate in this study

6age old over
No limit

Both

Vernal keratoconjunctivitis

Administration of ROH-201 ophthalmic solution

Change in clinical signs

ROHTO Pharmaceutical Co., Ltd.
IRB administrated by General incorporated associa tion of ethic committee for clinical trials
2-12-13, Shinjuku, Shinjuku-ku, Tokyo, Japan, Tokyo

+81-3-5050-4268

information@centriol-one.com

No

none